Neos Therapeutics, Inc. (NASDAQ:NEOS)’s share price shot up 3.2% during mid-day trading on Tuesday . The company traded as high as $11.15 and last traded at $10.10. 729,800 shares changed hands during mid-day trading, an increase of 31% from the average session volume of 555,959 shares. The stock had previously closed at $10.43.

A number of brokerages recently issued reports on NEOS. Cantor Fitzgerald began coverage on shares of Neos Therapeutics in a research report on Monday, July 31st. They issued an “overweight” rating and a $20.00 target price for the company. ValuEngine upgraded shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 12th. Zacks Investment Research upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. Royal Bank Of Canada set a $12.00 price objective on shares of Neos Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, August 8th. Finally, Cowen and Company restated a “buy” rating on shares of Neos Therapeutics in a research report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Neos Therapeutics has a consensus rating of “Buy” and an average target price of $14.00.

The company has a quick ratio of 2.84, a current ratio of 3.04 and a debt-to-equity ratio of 2.33.

Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.58) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.22. Neos Therapeutics had a negative net margin of 339.52% and a negative return on equity of 580.51%. The company had revenue of $6.70 million during the quarter. equities research analysts expect that Neos Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its stake in Neos Therapeutics by 167.9% during the second quarter. Russell Investments Group Ltd. now owns 270,020 shares of the company’s stock valued at $1,971,000 after buying an additional 169,237 shares in the last quarter. Essex Investment Management Co. LLC lifted its stake in Neos Therapeutics by 24.2% during the third quarter. Essex Investment Management Co. LLC now owns 238,152 shares of the company’s stock valued at $2,179,000 after buying an additional 46,423 shares in the last quarter. DAFNA Capital Management LLC lifted its stake in Neos Therapeutics by 120.3% during the second quarter. DAFNA Capital Management LLC now owns 209,873 shares of the company’s stock valued at $1,532,000 after buying an additional 114,600 shares in the last quarter. Virtu KCG Holdings LLC purchased a new stake in Neos Therapeutics during the second quarter valued at about $384,000. Finally, Schwab Charles Investment Management Inc. lifted its stake in Neos Therapeutics by 103.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 43,700 shares of the company’s stock valued at $320,000 after buying an additional 22,200 shares in the last quarter. 44.66% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/14/neos-therapeutics-inc-neos-shares-up-3-2.html.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Receive News & Stock Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related stocks with our FREE daily email newsletter.